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Abstract
Use of New Psychoactive Substances (NPS) has posed a global threat to public health and the security of the population.
As of December 2019, the NPS items identiﬁed in total have outnumbered by three to one the controlled substances listed in
the 1961 and 1971 UN Drug Conventions. However, most of these NPS have not been scheduled by the United Nations
because of their easy modiﬁcation on the chemical structures to shun control. Currently, the scheduling and control of NPS
is mostly at the national level and a rational scheduling of NPS by objective assessments is essential but often lacking. To
rationally schedule NPS, the NPS misuse situation was ﬁrstly estimated with the Taiwanese Substance Misuse Monitoring
and Reporting Systems (SMMRS) from 2006 through 2019. Then, the assessment of drug-related harms with an expert
Delphi procedure for drug scheduling was performed. The epidemiological analysis revealed that among 37 substances
commonly misused in Taiwan, heroin posed the highest risk, followed by (meth)amphetamine and ketamine. Of note,
misuse of NPS, such as ketamine, synthetic cannabinoids (JWHs, AM-2201, XJR-11), synthetic cathinones (MDPV, bkMDMA, 4 e MMC etc.), phenethylamines (PMMA, FMA, 2CeB, 2C-E etc.), piperazines (BZP, TFMPP) and tryptamines (5MeO-DIPT) has been on the rise. Though perceived drug-related harms differed among experts with different professional
backgrounds, the differences were not signiﬁcant. Four dimensions of drug-related harms– addiction, misuse, social harm
and physical harm– integrated from Nutt's model and scheduling criteria of Taiwan's Statute for the Prevention and
Control of Illicit Drugs (SPCID), were further divided into 11 indicators and applied to assess harms of the 37 substances.
Among the 11 indicators that corresponded to the four dimensions, 7 had signiﬁcant prediction capabilities. Additionally,
prevalence of misuse nationally was an important predictor of harm assessment. These indicators of harm assessment of
drug misuse can help develop a proper scheduling system for the management of controlled/illicit drugs. In conclusions,
drug scheduling is the ﬁrst step toward proper management of drug use problems. Facing the threats of NPS, it is
imperative to implement a rational and effective scheduling system for appropriate management. This study provides a
mechanism to scrutinize, and improve, the current evaluation process for NPS scheduling.
Keywords: Drug scheduling, Misuse trend, New psychoactive substances (NPS), Taiwan

1. Introduction
n the 20th Century, the enactment of three
United Nations Drug Conventions (the 1961
Single Convention on Narcotic Drugs, the 1971
UN Convention on Psychotropic Substances and
the 1988 UN Convention against Illicit Trafﬁc in
Narcotic Drugs and Psychotropic Substances) has
been the foundation up to the present day international drug control system. However, in recent
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years, use of new psychoactive substances (NPS)
has emerged as a new threat to public health and
social security because of the elusiveness of this
use from the UN Drug Conventions and the
drugs’ uncertain toxicological proﬁles [1, 2]. NPSs
are deﬁned by the United Nations Ofﬁce on
Drugs and Crime (UNODC) as substances that
are not controlled under the 1961 or 1971 UN
Drug Conventions and predominantly derivatives
or analogues of existing controlled substances [3,
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4]. They are classiﬁed into 9 categories, including
synthetic cannabinoids, synthetic cathinones, ketamine and PCP-type substances, phenethylamines, piperazines, tryptamines, aminoindanes,
plant-based substances and others [5]. As of
December 2019, The UNODC had identiﬁed a
total of 950 NPS, a number that is more than 3
times the 273 substances listed in the 1961 and
1971 conventions [6].
Owing to the lack of an international consensus
on the legislative control of NPS, at present,
scheduling of NPS mainly depends on the national
legislation and drug policy. In Taiwan, NPS are
also scheduled as controlled substances according
to the national drug-related laws that were enacted
primarily for the control of known traditional
addictive (dependence-inducing) drugs. Our previous study on the comparison of the legislative
mechanism for NPS control between Taiwan,
South Korea and Japan indicated that rigid criteriadaddictive potential, abuse liability and social
harm liability d for scheduling NPS as controlled
substances may explain why Taiwan controlled the
fewest NPS items [7]. Therefore, for effective NPS
control in Taiwan, timely and ﬂexible legislative
mechanisms with a sensitive monitoring system
and quick response to comprehensive scientiﬁc
evidence about the rapidly emerging NPS are
essential [7].
Nutt et al. have demonstrated the importance of
rational scheduling for drug control using a ninecategory of harm model with an expert Delphi
procedure [8]. This model evaluated drug-related
harms with nine parameters grouped into three
dimensions–physical harm, dependence and social
harms– to develop a rational scale for assessment of
the harm of drugs. However, the model did not take
individual drug misuse into consideration. Take
Taiwan for example– the misuse of ketamine and
amphetamine(s) has been more prevalent than that
of cocaine and street methadone, but it would not be
counted as a contributing factor of misuse liability.
In other words, the nine-category of harm model
did not fully correspond to the legislative criteria of
addictive potential, misuse liability and social harm
liability to schedule controlled substance in Taiwan.
In Taiwan, misuse of club drugs, including
MDMA, ketamine, ﬂunitrazepam, and zolpidem,
revealed a new pattern of drug use since the early
2000s as determined by ketamine-positive urine
samples and increased ketamine seizures [9]. The
harms caused by ketamine, including dependence,
cognitive impairment, emergence phenomenon,
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and interstitial cystitis, may be greater than expected [8, 10]. Ketamine has been placed as a
schedule III drug in Taiwan since 2002. Because of
its predominant abuse and toxicological effects,
rescheduling of ketamine to schedule I or II has
been debated in recent years. Besides ketamine, the
misuse of some other NPS, such as cathinones and
synthetic cannabinoids has also been a new concern
[9, 11]. However, some NPS are yet to be controlled
due to the rigid criteria of drug scheduling.
As noted, national laws control appropriate NPS
scheduling. In this study, the three legislative
criteria of addictive potential, misuse liability and
social harm liability were taken into consideration to
determine indicators of drug-related harms for
assessment beginning with misuse in Taiwan. The
epidemiological data of drug seizure and use were
collected from “Drug abuse cases and test statistics
data” [12] and weighted as an indicator for misuse
liability. Then, Nutt's nine-category matrix of harm
model was modiﬁed to compare the drug-related
harms with and without consideration of the
epidemiological data on misuse. Using these
criteria, we present an objective and comprehensive
evaluation of the potential of NPS-related harms for
appropriately suitable scheduling.

2. Materials and Methods
For rational scheduling of NPS, NPS misuse data
was ﬁrst evaluated using epidemiological approaches. The misuse data of major traditional
drugs served as a reference for comparison. Then,
the assessment of drug-related harms with an
expert Delphi procedure for drug scheduling was
conducted.
2.1. Data collection
Drug misuse data representing both the supply
and demand sides was obtained from the Substance
Misuse Monitoring and Reporting Systems
(SMMRS), maintained on a monthly basis by the
Taiwan Food and Drug Administration (TFDA) of
the Ministry of Health and Welfare (MOHW). The
subsystems of SMMRS brieﬂy described below [12].
2.1.1. Data collection subsystem on arrests and drug
seizures (SADS)
The data, collected monthly, was from the Investigation Bureau, Ministry of Justice; the National
Police Administration, Ministry of Interior; and the
Headquarters of Military Police, Ministry of Defense; data used was from 2006 through 2019.
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2.1.2. Data collection subsystem on laboratory drug
testing of urine (LDTU) for court referrals
The data collected here included sources just
described with the addition of all local health
departments.
2.1.3. Reporting subsystem for addiction treatment
(RSAT)
Data was collected from the MOHW-designated
150 psychiatric hospitals for addiction treatment
from 2006 through 2019. In this subsystem, cases of
substance misuse were reported online.
2.2. Evaluation of drug-related harms with an
expert Delphi procedure
The evaluation of harm using an expert Delphi
procedure was conducted with a modiﬁcation of the
procedure outlined by Nutt et al. [8]. Harms of
drugs were evaluated with each expert providing
scores separated into three dimensions: physical
harm, dependence and social harms. Each dimension was further divided into three aspects of harm.
The dimension of physical harm consisted of acute,
chronic and intravenous harm; the dimension of
dependence included intensity of pleasure, psychological dependence and physical dependence;
and the dimension of social harms included intoxication, other social harms and health care costs.
Nutt's nine indicators of harm did not include
epidemiological misuse-related outcomes. In
Taiwan, according to the mandate of the Statute for
the Prevention and Control of Illicit Drugs (SPCID),
a substance can only be scheduled as a controlled
drug if it possesses all three characteristics: addictive potential, misuse liability and social harm liability, deﬁned as follows:
(1) Addictive potential: euphoria, withdrawal and
psychological dependence.
(2) Misuse liability: international misuse prevalence, national misuse prevalence and different
regulations among different countries.
(3) Social harm liability: infectious hazard, criminality and poly-drug use hazard.
This SPCID-based scheduling system, on the other
hand, did not factor physiological harm into account.
Therefore, this study tried to incorporate the harmbased approach of Nutt et al. and the SPCID-based
scheduling principles of addictive potential, misuse
liability and social harm liability by adding the fourth
dimensiondphysical harm. For the Delphi survey,
these 4 dimensions of harm were further divided into
11 indicators as shown in Table 1: euphoria,

withdrawal,
pharmacokinetics,
psychological
dependence, international prevalence, national
prevalence, criminality (violent attacks, accidents,
etc.), social costs (work loss, medical costs), acute
physical hazards, chronic physical hazards, and
infection
hazards
(communicable
disease
transmission).
Twenty-three experts in the ﬁelds of biomedical
(addiction and physical harm) and social sciences
(misuse and social hazard) were invited to participate in the risk assessment of 37 commonly used
drugs/substances (15 traditional substances, 18 NPS
and 4 non-scheduled substances). The survey was
focused on the harm scored with 11 indicators on
these 37 addictive substances most often used
improperly. The expert opinion was carried out in
two stages. In the ﬁrst stage, we provided the deﬁnitions of assessment indicator and questionnaire
for experts to ﬁll in the substance hazard assessment
scores. In the second stage, in addition to the results
of the survey obtained from the opinions of experts
in the ﬁrst stage, we also provided the participating
experts reference information such as the legal
classiﬁcation and misuse situations of relevant
substances in the UN, USA, UK, Canada, Singapore
and Taiwan, as well as toxicological proﬁles of these
substances. There were 19 experts participated in
the ﬁrst stage and 18 in the second stage.
2.3. Data analysis
Statistical analysis was performed with SPSS
version 20.0. Data was tested by t test, pared-t test,
one way ANOVA, and multiple linear regression
with a p-value <0.05 determining a statistically signiﬁcant difference.
To determine the accuracy of the prediction
model, the root mean squared error (RMSE) was
applied [13, 14]. The RMSE is a standard method to
measure the error of a model in predicting quantitative data. In this study, it serves as an estimator for
the standard deviation s of the distribution of the
errors from our model's prediction.

3. Results
3.1. Analysis of drug misuse trends in Taiwan
3.1.1. The supply side
3.1.1.1. Seizures of major illegal drugs.
According to the data of SADS, the conﬁscated
amounts of ketamine, a major NPS category, prevailed all drug seizures from 2006 to 2019 in Taiwan.
There were three peaks of ketamine seizures in

Table 1. Indicators of three different models for evaluation of drug-related harms.
Parameters of Nutt's model
Category

Parameter

Dependence

Intensity of pleasure
Physical dependence
Psychological dependence
Intoxication
d
d
Other Social harms
Health-care costs
Acute
Chronic
Intravenous harm

Social harm

Physical harm

Indicators based on SPCID

Integrated Indicators in this study
Category

Indicator

Addiction

Addiction

Misuse

Misuse

Social harm

Social harm

Euphoria
Withdrawal
Psychological dependence
Pharmacokinetics
International misuse prevalence
National misuse prevalence
Criminality
Health-care costs
Acute
Chronic
Infectious hazard

Physical harm
d

2010, 2014 and 2019, and each peak was much
higher than the previous one (growth rate>26%). A
record high of 3,303 Kg of ketamine was seized in
2014 and then gradually decreased yearly, though
still greater than 1,000 kg/year after 2016 (Fig. 1).
Ketamine was the most highly seized drug at 1,599.7
Kg/year, followed by (meth) amphetamine 399.0 Kg/
year, heroin 146.5 Kg/year and cannabis 66.0 Kg/
year. The seizure of (meth)amphetamine, a major
misused drug in the 1990s in Taiwan, resurged in
recent years and in one year (2018) exceeded ketamine seizures. Overall, ketamine and (meth)
amphetamine were the most seized drugs in Taiwan
over this period of time, followed by heroin,
cannabis and nimetazepam (Fig. 1-A).
3.1.1.2. Seizures of NPS other than ketamine.
Seizures of large quantities of ketamine over the
years indicated the NPS issue deserves attention
(Fig. 1-B). Besides ketamine, other NPS, mainly
synthetic cathinones, synthetic cannabinoids and
phenethylamines, have also been seized. The results
showed that after XLR-11, a synthetic cannabinoid,
was regulated as a schedule III drug in 2014, its
seizure in 2015 was signiﬁcantly reduced to none.
Synthetic cathinones, such as MDPV and bkMDMA, also showed seizures decreased signiﬁcantly after regulation (Fig. 1-B).
Para-methoxymethamphetamin (PMMA), a phenethylamine-type NPS, has been controlled as a
schedule II drug and was ﬁrst seized in 2009 at 30.2
grams, and except for a seizure of 960.1 grams in
2015, there were no further seizures. In 2015,
methoxymethcathinone was regulated as a schedule
II drug. Except for 3,240.8 grams seized at the same
year, there were no further seizures.
In contrast, seizures of some NPS continued to
increase signiﬁcantly after regulation. Synthetic
cathinones such as mephedrone and bk-MDMA

were continuously seized each year after being
regulated from 2014 to 2019 as shown in Fig. 1-B.
3.1.1.3. Laboratory drug testing of non-urine (conﬁscated
chemical) samples.
Results of drug testing on non-urine samples
elucidate which substances have been possessed or
sold. According to the total cases of positive substances detected from 2006 to 2019, the main substances in order were: (meth)amphetamine, ketamine,
heroin, nimetazepam, mephedrone, methyl-a-ethylaminopentiophenone (MEAPP), bk-MDMA, MDMA,
XLR-11, and methoxymethamphetamine. In addition
to ketamine, the average annual positive cases of some
NPS, such as mephedrone, MEAPP and bk-MDMA
were all more than 3,000 cases/year; XLR-11 was more
than 1,000 cases/year and methoxymethamphetamine
423 cases/year, revealing that NPS problems deserve
our attention (Fig. 2-A). Of note, multi-component
substances detected in non-urine samples have
become more prevalent in recent years.
The results of positive cases detected in non-urine
samples can also be approached by category as
follows:
(1) Phenylethylamines: (Meth)amphetamine was
the most predominant substance, followed by
MDMA and PMMA. The samples detected with
phenylethylamine mainly contained a single
component, but multiple components have been
detected in recent years. The cases of methoxymethamphetamine (PMMA) decreased yearly
since its regulation in 2006 except for a transient
increase in 2007.
(2) Ketamine: Cases of ketamine gradually
increased from 2006 to 2015 with a peak of over
30,000 cases yearly in 2014 and 2015, and then
decreased from 2016 to 2019 although still
maintained over 20,000 cases per year.

ORIGINAL ARTICLE

171

JOURNAL OF FOOD AND DRUG ANALYSIS 2021;29:168e181

172

JOURNAL OF FOOD AND DRUG ANALYSIS 2021;29:168e181

ORIGINAL ARTICLE
Fig. 1. Seizures of (A) major illegal drugs (B) illegal NPS other than ketamine in Taiwan from 2006 through 2019.
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Fig. 2. Positive drug testing cases of (A) non-urine samples and (B) urine samples in Taiwan.
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(3) Opioids: Cases detected with heroin as the single component ﬂuctuated around 20,000 per
year. Sporadic cases of acetylcodeine and acetylmorphine, which have not been regulated,
were also reported (data not shown). These two
unregulated items were mainly detected in cases
with multiple drugs.
(4) Cathinones: Since 2009, several synthetic cathinones, including mephedrone, MEAPP and bkMDMA, have been detected. They were mainly
detected with multiple drugs. Among them, the
number of positive cases of mephedrone
(schedule III) increased sharply from 2015 to
2019. MEAPP was regulated in 2017. The number of MEAPP positive cases increased from
2016 to 2018, then decreased in 2019. bk-MDMA
was regulated in 2012. The number of bkMDMA positive cases increased from 2012
to2015 yearly, then dropped signiﬁcantly in 2016.
(5) Cannabis: Cases of cannabis without other drugs
were mainly detected from 2006 to 2011. In 2012,
about half of cases with cannabis and other
drugs were detected. Then the number of positive samples containing cannabis and multiple
components increased annually. Among them,
XLR-11 was regulated in 2014. In 2014, the
number of XLR-11 positive cases was 411. Then
in 2015, the number of positive cases increased
signiﬁcantly to 3,689 and the number of positive
cases was also detected every year.
(6) Tryptamines: Cases of tryptamines were mainly
detected in samples with multiple drugs. 5MeO-MIPT (schedule III) was the major tryptamine-type NPS. The number of 5-MeO-MIPT
positive cases increased signiﬁcantly in 2015 and
2017. 5-MeO -DIPT (schedule IV) was also
detected sporadically.
(7) Piperazines: Cases of piperazines were mainly
detected
with
multiple
drugs.
Triﬂuoromethylphenylpiperazine (schedule III) was
the most commonly detected, followed by N-Benzylpiperazine (schedule II). Both positive cases
detected in 2014 were signiﬁcantly on the rise since.
3.1.2. The Demand side
Based on the results of “2014 National Substance
Abuse Survey”, the prevalence of illegal drugs
among 12 to 64 ages in Taiwan was 1.29%. The most
commonly misused illegal drugs were in the
following order: amphetamine(s) (0.60%), ketamine
(0.39%) and cannabis (0.30%) [15].
3.1.2.1. Drug addiction treatment.
Data on drug mentions among Treatment Admissions
indicate
that
heroin
and

methamphetamine remained the two predominant
drug problems from 1999 to 2019, heroin increased
from 902 mentions in 1999 to 16,891 mentions in
2019 and methamphetamine increased from 1,120
mentions in 1999 to 13,038 mentions in 2019; while
ketamine-dependent admissions increased from 99
mentions in 2006 to 1,760 mentions in 2019. From
2006 to 2019, ketamine increased from 0.6% to 5.1%
(Fig. 3). Other than ketamine, the treatment mentions related to NPS misuse have only been reported
since 2014.
In 2019, heroin (49.4%) and (meth)amphetamine
(38.0%) remained the two most prevalent drugs in
the mentions of treatment admissions, followed by,
ketamine (5.1%), MDMA(2.3%) and cannabis (1.7%).
In treatment mentions of NPS other than ketamine,
FMA (51.7%) was the most prevalent drug, follow by
MDPV (10.0%), CMA (10.0%), Mephedrone(8.3%),
Thiamylal (5.0%) and K2 (5.0%) as shown in Fig. 3.
3.1.2.2. Urine drug testing.
(Meth)amphetamine, heroin, ketamine and
MDMA were found among results of urine tests in
persons suspected of using drugs, as shown in Fig. 2-B
with average annual positive cases of: (meth)
amphetamine 36,329, heroin 21,056, Ketamine 14,560
and MDMA 1,052. Ketamine positive cases were much
more than many schedule II drugs such as: MDMA,
morphine-N-oxide (615 cases/year), codeine ( 5%)
(232 cases/year), and cannabis (211 cases/Year).
Since ketamine was placed as a schedule III drug
in 2002 [10], the positive cases have increased substantially from 2006 to 2013. Although there was a
transient decrease from 2015 to 2017, ketamine
positive cases increased again from 2018 to 2019.
Since 2012, the number of ketamine positive cases
was even higher than that of morphine positive
cases, which were interpreted as heroin use after
metabolism.
While the majority of positive urine samples
identiﬁed were single drugs, cases with multiple
drugs increased year by year. Speciﬁcally, eightyeight single substances were detected in urine
samples from 560,096 people testing positive, while
2,310 multiple substances were identiﬁed from
300,294 positive cases in urine samples from 2006 to
2019. The detection of single substance accounted
for 65% of the total number of positive samples, and
the multiple substances accounted for 35%. Besides
ketamine, other NPS included: synthetic cathinones
(bk-MDMA, bk-MBDB, bk-MBDB, bk-DMBDB,
Ethylone, CMC, CEC, Cl-Alpha-PVP); and phenethylamines (2C-E).
As of December 2019, all regions/countries around
the world have reported 950 items of NPS to the
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Fig. 3. Proportions of Different Drug Mentions among Treatment Admissions to Hospitals in Taiwan from 1999 through 2019.
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United Nations Ofﬁce on Drugs and Crime
(UNODC). By contrast, in Taiwan, by the end of 2019,
there were only 52 NPS items scheduled. These 52
NPS items are described by the category as follows:
(1) Synthetic cannabinoids: 9 schedule III drugs
(JWH-018, JWH-073, JWH-250, HU-210, CP47,497, JWH-122, AM-2201, XLR-11 and ABPINACA).
(2) Synthetic cathinones: 3 schedule II drugs (MDPV,
methoxymethcathinone and Alpha-PVP); 17
schedule III drugs (mephedrone, methylone, 4methylethcathinone, ﬂuoromethcathinone, 3,4methylenedioxy-N-ethylcathinone,
chloromethcathinone, bromomethcathinone, butylone,
methylbutylone,
methylpentedrone,
chloroethcathinone, methyl-N-benzylcathinone, ClAlpha-PVP, ethylmethcathinone, Chloro-a-PPP,
ethylethcathinone and methyl-N,N-dimethylcathinone)
and
1
schedule
IV
drug
(chlorodimethylcathinone).
(3) Ketamine and PCP-type substances: 3 schedule
III drugs (Ketamine, methoxetamine and
ﬂuoroketamine).
(4) Phenethylamines: 6 schedule II drugs [N,NDimethylamphetamine,
p-methoxymethamphetamine, ﬂuoromethamphetamine,
chloromethamphetamine, lisdexamphetamine
and
(2-methylaminopropyl)benzofuran];
6
schedule III drugs (4-bromo-2,5-dimethoxyphenethylamine,
p-methoxyethylamphetamine,
chloroamphetamine,
25BeNBOMe,
ﬂuoroamphetamine
and
2,5dimethoxyphenethylamine).
(5) Tryptamines: 1 schedule III drug (5-MeO-MIPT);
1 schedule IV drug (5-MeO-DIPT)
(6) Piperazines: 1 schedule II drug (1-benzylpiperazine);
1
schedule
III
drug
[1-(3triﬂuoromethylphenyl)].
(7) Plant-based substances: 2 schedule II drugs
(peyote and khat). 1 schedule III drug (kratom).
Most of the regulated items were schedule II and
schedule III substances. The NPS items regulated as
schedule II were mostly amphetamine isomers or
analogues. The schedule III of NPS were mainly
synthetic cathinones and synthetic cannabinoids.
3.2. Assessment of drug-related harms with an
expert Delphi procedure for drug scheduling
3.2.1. Evaluation of harm scores
The ranking of substances of misuse by harm
scores based on 9 assessment parameters of Nutt's
research is shown in Fig. 4-A; 8 indicators based on

Taiwan's Statute are shown in Fig. 4-B and 11
assessment parameters of this research are shown in
Fig. 4-C. There were signiﬁcant differences between
the 11 evaluation indicators in this study, the 8 indicators based on Taiwan's SPCID and the 9
assessment parameters obtained by the Nutt study
(p-value ¼ 0.000 < 0.05 by t test).
The result of ranking according to harm assessment scores of 37 common misuse substances is
shown in Fig. 4. The top ten substances based on
Nutt's 9 parameters were heroin, cocaine, amphetamine, fentanyl, 2C series, MDMA, alcohol, MDPV,
PMMA and 25BeNBOMe; the top ten based on 8
indicators on Taiwan's SCPID were: heroin,
amphetamine, cocaine, fentanyl, alcohol, MDMA,
2C series, MDPV, ketamine and Oxycodone; and
based on the 11 indicators in the integrated study
were: heroin, amphetamine, cocaine, fentanyl,
alcohol, MDMA, 2C series, MDPV, ketamine and
PMMA. While heroin was ﬁrst on each list, cocaine,
amphetamine and fentanyl were 2 through 4 on
each list, though in different order.
According to Fig. 4, we found the ranking of
traditional drugs by the harm scores to have been
affected by the indicator of misuse prevalence.
Speciﬁcally in the United Kingdom, where cocaine
misuse was more serious, the harm score of cocaine
ranked second whereas in Taiwan, amphetamine
ranked second because of its perceived severity.
The harm score ranking of NPS varied in these 3
models. The top 5 by Nutt's 9 parameters were 2C
series, MDPV, PMMA, 25-NBOMe and BZP; by 8
indicators based on Taiwan's SPCID were 2C series,
MDPV,
ketamine,
BZP
and
Triﬂuoromethylphenylpiperazine (TFMPP); by 11 indicators in this study were 2C series, MDPV,
ketamine, PMMA and 25-NBOMe.
Results from the experts indicated that the harm
caused by certain NPS was greater than many other
schedule II controlled drugs, such as cannabis, GHB
and methadone. Although alcohol was not a
controlled drug, experts gave it higher harm scores
than MDMA, cannabis, GHB, etc. The harm scores
rank is shown in Fig. 4.
3.2.2. Mean harm scores between 2 stages
After reviewing the harm assessment scores of the
individual substances, a comparison of the harm
scores between stage 1 and stage 2 was performed.
The results indicate they were not statistically
different (Fig. 5, p-value > 0.05 by t test).
3.2.3. The prediction model analysis
Since there was no signiﬁcant difference between
the two stages, we used the harm scores of stage 2 to
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Fig. 4. Rank of mean harm scores for 37 substances based on (A) Nutt's 9 parameters; (B) 8 indicators based on Taiwan's Statute and (C) 11 indicators
in this study.
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conduct a linear regression prediction analysis; we
selected important impact indicators for these 3
models.
3.2.3.1. Model A: Nutt's 9 parameters.
We analyzed the predictive ability of Nutt's 9
parameters for schedule levels (Y) of substance use
by linear regression, selecting 7 indicators with
signiﬁcant prediction capabilities: criminality (Xa1),
euphoria (Xa2), health-care costs (Xa3), acute physical harm (Xa4), chronic physical harm (Xa5), withdrawal (Xa6)and international misuse prevalence
(Xa7). he prediction model for estimating the
schedule levels of control drug was as follows:
Y ¼ 0.518Xa1þ0.383Xa2-0.372Xa3þ0.315Xa4-0.268Xa50.111Xa6þ0.101Xa7
There was no multicollinearity among these variables; the model was found to have 49.9% explanatory power.
3.2.3.2. Model B: 8 indicators based on Taiwan's
SPCID.
We then analyzed the predictive ability of 8 indicators based on Taiwan's SPCID for schedule levels
(Y) of substance use, selecting 6 indicators with signiﬁcant prediction capabilities: criminality (Xb1),

euphoria (Xb2), health-care costs (Xb3), national
misuse prevalence (Xb4), withdrawal (Xb5) and psychological dependence (Xb6). The prediction model
for estimating the schedule levels of control drug was:
Y ¼ 0.643Xb1þ0.409Xb2-0.352Xb3-0.193Xb40.146Xb5þ0.112Xb6
Again, with no multicollinearity, the prediction
model was found to have 48.5% explanatory power.
3.2.3.3. Model C: 11 indicators in this study.
We further analyzed the predictive ability of 11
indicators for schedule levels (Y) of substance use by
linear regression and selected the 7 indicators from
the ﬁrst model, but added two, national misuse
prevalence and infectious hazard. The prediction
model for estimating the schedule levels of control
drug was:
Y ¼ 0.468Xc1þ0.353Xc2-0.278Xc3-0.211Xc4þ0.288Xc50.245Xc6þ0.144Xc7 -0.129Xc8þ0.097Xc9
With no multicollinearity, the prediction model
had 52.4% explanatory power. Based on this, the
predictive explanatory power of model C was better
than the other two models and was explained by the
health-care costs, national misuse prevalence,
chronic physical harm and withdrawal have positive

Fig. 5. Comparison of the mean harm scores for 37 substances between stage 1 and stage 2.

regression. The national misuse prevalence and international misuse prevalence both were important
indicators for harm assessment.
The variance inﬂation factor (VIF) of each
parameter for the prediction model was between
1.674 to 4.432, indicating that there was no collinearity between parameter and the prediction model.
The p-values with t-test between parameters for the
prediction models were all less than 0.001, demonstrating these parameters were predictive. The pvalues of the t-test between two models were less
than 0.000, indicating that there were signiﬁcant
differences between the models. The RMSE (Root
mean squared error) of these 3 models was 0.8062
(model A), 0.8167 (model B) and 0.7849 (model C),
respectively, showing that the deviation of model C
was the smallest.

4. Discussion
Misuse of NPS has posed a global threat to public
health but most NPS have not been controlled
because of their easy modiﬁcation on the chemical
structures and lack of misuse information. Our
previous research demonstrated that Taiwan
controlled the least NPS items among the Northeastern countries because of rigid criteria to
schedule an NPS item [7, 11]. According to Taiwan's
SPCID, a substance cannot be scheduled as a
controlled drug unless it possesses all three characteristics: addictive potential, misuse liability and
social harm liability. It explains why there were only
52 NPS items scheduled by the end of 2019 in
Taiwan as shown in the results. Therefore, it would
be a priority to schedule a potentially addictive
substance or an NPS item before it becomes an
issue.
To rationally schedule a potentially addictive
substance, Nutt et al. developed a nine-category of
harm model with an expert Delphi procedure [8].
However, this model did not take misuse situation
of a potentially addictive substance into consideration. In contrast, the criteria of Taiwan's SPCID did
not take the factors of physical harm into account.
Thus, in this study, the current situation of drug
misuse was ﬁrst evaluated using epidemiological
approaches. From the results of the supply side on
drug seizures (Fig. 1, 2-A) and demand side on the
scale of drug misuse (Fig. 2-B, 3), we found that
ketamine, (meth)amphetamine and heroin have
been the most prevalent drugs in Taiwan. While
(meth)amphetamine and heroin have been the
predominant drugs for several decades, ketamine
misuse has not been a problem until the early 2000s
[9, 10]. The NPS other than ketamine, such as
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synthetic cannabinoids (XLR-11, JWHs); synthetic
cathinones (MDPV, methoxymethcathinone, 4MEC, bk-MDMA, mephedrone, MEAPP); phenethylamines (PMMA, FMA, CMA, 2CeB, 2C-E); and
piperazines (BZP, TFMPP) have also been on the
rise (Fig. 1-B, 2-A and 3).
It should also be noted that the detection capability of drug use from urine samples were limited
by the availability of screening tools (such as test
kits or assay methods) to screen and/or drug standards to conﬁrm a speciﬁc drug. Since many, if not
most, NPS have not been scheduled for control, the
assay methods or standard preparations for NPS
detection are often not available. As a result, the
misuse situation of an emerging NPS item may be
underestimated.
In reference to the drug misuse situations, the
assessment of drug-related harms with an expert
Delphi procedure for drug scheduling was conducted. Three models were applied to analyze and
rank the harms of 37 substances, including legal
addictive substances, traditional drugs and NPS. As
shown in Fig. 4-A, Nutt's model did not take the
misuse situation into consideration and it may
explain why the ranking score of cocaine was higher
than that of methamphetamine in the SPCID model.
On the other hand, the SPCID model did not take
the factors of physical harm into account (Fig. 4-B).
As a result, the harm score ranking of PMMA was
lower in the SPCID model than that of Nutt's model
even though PMMA caused many fatalities in recent
years [11]. Therefore, for effective and rational drug
scheduling, drug-related harms were integrated
from Nutt's model and Taiwan's Statute for the
Prevention and Control of Illicit Drugs (SPCID) into
four dimensions, namely, addiction, misuse, social
harm and physical harm (Table 1). These four dimensions were further divided into 11 indicators
and applied to assess harms of the 37 substances.
Among the 11 indicators that corresponded to the
four dimensions, 7 had signiﬁcant prediction
capabilities.
According to the analysis of the integrated results
(Fig. 4-C), heroin posed the highest risk, followed by
(meth)amphetamine and ketamine. The harm
scores of two schedule III NPS (ketamine and synthetic cathinones) and a legal substance (alcohol)
were higher than those of some schedule II drugs
(such as cannabis, PCP, GHB and methadone),
indicating the harm of some NPS, at least ketamine
and synthetic cathinones in this study, may have
been underestimated.
From the misuse statistics shown in Fig. 1-B, we
could also observe that regulatory intervention
would have some impacts on the misuse of NPS as
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evidenced by the quantity of NPS seizures that
dropped signiﬁcantly after regulation. PMMA,
regulated as a schedule II drug in 2006, only seized
in 2009 at 30.2 grams, and 960.1 grams in 2015, and
there were no further seizures. Methoxymethcathinone was regulated as a schedule II drug
in 2006 and only 3,240.8 grams were seized at the
same year, no further seizures. Misuse of synthetic
cathinones such as MDPV, mephedrone, methoxymethcathinone and bk-MDMA deserves further
attention. Their seizures had declined after regulation, but were still seized every year. Therefore, an
appropriate scheduling system is crucial to effectively control NPS misuse.
The results of LDTU (Fig. 2-A and 2-B) indicated
multi-component substances detected in the urine
specimens or non-urine specimens have become
more prevalent in recent years. Although single
addictive substances were still the majority in the
positive urine specimens, positive urines detected
with more than 5 substances were increasing,
especially in 2018 and 2019. One urine specimen
even contained more than 15 components. The
proportion of non-urine specimens with two components increased from 16.2% in 2006 to 55.0% in
2019. In 2014, 23 specimens were tested positive with
16 components, and 11 specimens were tested positive with 15 components in 2016. In 2019, one nonurine specimen was found to contain 15 addictive
substances. Multiple drugs in the NPS increase the
health risk that cannot be ignored. It is suggested
that precautionary measures should be taken for
preventive purposes.
In this study, national prevalence of misuse was
shown as an important predictor of harm assessment. These 11 indicators of harm assessment of
misuse of drugs can help develop a proper scheduling system for the management of controlled/
illicit drugs.

5. Conclusions
Use of NPS has been a global concern. The misuse
of NPS in Taiwan, initiated in the early 2000s with
ketamine misuse, has been extended to include
synthetic cathinones, such as mephedrone, MEAPP,
bk-MDMA and MDPV; synthetic cannabis, such as
XLR-11 and K2 (JHWs); and phenethylamines, such
as PMMA and 2C series. So far, only 52 NPS had
been scheduled, a number far less than the 950þ
NPS deﬁned by the UNODC. It could be due to
Taiwan's current rigid criteria in the SPCID e
addictive potential, abuse liability, and social harm
liability e to schedule speciﬁc drugs as controlled
substances [11].

We have also shown that Taiwan's scheduling
principle did not include the physical harm as an
assessment indicator, while the research by Nutt et
al. ignored the inﬂuence of national misuse prevalence. Therefore, based on analysis of the predictive
ability of indicators, we integrated the Nutt's and
Taiwan's SPCID models into the model C to estimate the drug-associated harm for appropriate
scheduling. Addiction, misuse and social hazard
were all important factors to assess harms in the
model. These indicators can be used for the harm
assessment of misused drugs that helps develop a
rational and site-speciﬁc scheduling system for the
management of controlled/illicit drugs.
Proper drug scheduling is the ﬁrst step in the
management of drug use problems. Facing the
threats of NPS misuse, it is imperative to implement
a rational and effective scheduling system for
appropriate management. This study provides a
mechanism to scrutinize, and hopefully to improve,
the current evaluation process for drug scheduling.
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